1.Great attention should be paid to the adverse drug reactions associated with the use of molecular targeted anticancer drugs.
Zheng-tang CHEN ; Yu-zhong DUAN ; Jian-cheng XU
Chinese Journal of Oncology 2009;31(12):881-884
Antineoplastic Agents
;
adverse effects
;
therapeutic use
;
Diarrhea
;
chemically induced
;
Drug Delivery Systems
;
methods
;
Exanthema
;
chemically induced
;
Humans
;
Leukopenia
;
chemically induced
;
Lung Diseases, Interstitial
;
chemically induced
;
Myocardial Infarction
;
chemically induced
;
Neoplasms
;
drug therapy
;
Tumor Lysis Syndrome
;
etiology
2.Antibiotics-associated Diarrhea and Other Gastrointestinal Abnormal Responses Regarding Helicobacter pylori Eradication.
Soon Beom KWON ; Kook Lae LEE ; Joon Suk KIM ; Jae Kyung LEE ; Won KIM ; Yong Jin JUNG ; Ji Bong JEONG ; Ji Won KIM ; Byeong Gwan KIM
The Korean Journal of Gastroenterology 2010;56(4):229-235
BACKGROUND/AIMS: Helicobacter pylori (H. pylori) is closely related with a wide range of gastrointestinal disease. One-week triple therapy is currently considered as the golden standard for the treatment of H. pylori infection. However, gastrointestinal abnormal responses are major pitfalls in such regimen. The aim of this study was to identify symptoms, frequency and severity of antibiotics-associated gastrointestinal abnormal responses during H. pylori eradication therapy. METHODS: Sixty-seven patients with H. pylori infection between September 2005 and March 2006 were included. After 1 week of H. pylori eradication triple therapy (rabeprazol 10 mg, clarithromycin 500 mg, amoxicillin 1 g bid), we evaluated gastrointestinal abnormal responses (diarrhea, bloating, constipation, abdominal pain, borborygmus, flatulence, stool frequency, belching, and nausea) and severities every week for 4 weeks. RESULTS: The incidence of diarrhea was the highest in week 1, which was 41.28% (n=28) and the lowest in week 4, which was 9.52% (n=6) and decreased from week 1 to week 4 with statistical significance (p<0.0001). The most common gastrointestinal abnormal responses were associated with flatulence in week 1 (n=21, 31.34%), week 2 (n=21, 33.33%) and abdominal distention in week 3 (n=16, 25.40%), week 4 (n=15, 23.81%). Most of gastrointestinal abnormal responses were mild, and the most common symptom with higher than moderate grade was abdominal pain (n=4, 40.00%) in week 1. Alcohol consumption and coexisting medical illness were not associated with diarrhea (p=0.0852, 0.9009 respectively). CONCLUSIONS: H. pylori eradication therapy is commonly associated with antibiotics-associated gastrointestinal abnormal responses, which may result in antibiotics intolerance and H. pylori eradication failure. Even though those symptoms are not so severe, we have to consider the gastrointestinal abnormal responses associated with H. pylori eradication, especially diarrhea.
Abdominal Pain/chemically induced
;
Adult
;
Alcohol Drinking
;
Anti-Bacterial Agents/*adverse effects/therapeutic use
;
Diarrhea/*chemically induced
;
Female
;
Flatulence/chemically induced/etiology
;
Gastrointestinal Diseases/*chemically induced
;
Helicobacter Infections/*drug therapy
;
*Helicobacter pylori
;
Humans
;
Male
;
Middle Aged
;
Young Adult
3.A Case of Pseudomembranous Colitis Associated with Rifampin.
Ji Young PARK ; Joon Seok KIM ; Sun Jong JEUNG ; Myung Sook KIM ; Seok Chan KIM
The Korean Journal of Internal Medicine 2004;19(4):261-265
Pseudomembranous colitis is known to develop with long-term antibiotic administration, but antitubercular agents are rarely reported as a cause of this disease. We experienced a case of pseudomembranous colitis associated with rifampin. The patient was twice admitted to our hospital for the management of frequent bloody, mucoid, jelly-like diarrhea and lower abdominal pain that developed after antituberculosis therapy that included rifampin. Sigmoidoscopic appearance of the rectum and sigmoid colon and mucosal biopsy were compatible with pseudomembranous colitis. The antitubercular agents were discontinued and metronidazole was administered orally. The patient's symptoms were resolved within several days. The antituberculosis therapy was changed to isoniazid, ethambutol and pyrazinamide after a second bout of colitis. The patient had no further recurrence of diarrhea and abdominal pain. We report here on a case of pseudomembranous colitis associated with rifampin.
Aged
;
Aged, 80 and over
;
Antibiotics, Antitubercular/*adverse effects
;
Diarrhea/etiology
;
Enterocolitis, Pseudomembranous/*chemically induced
;
Humans
;
Male
;
Rifampin/*adverse effects
;
Tuberculosis, Pulmonary/drug therapy
4.Environmental and health effects associated with Harmful Algal Bloom and marine algal toxins in China.
Biomedical and Environmental Sciences 2004;17(2):165-176
The frequency and scale of Harmful Algal Bloom (HAB) and marine algal toxin incidents have been increasing and spreading in the past two decades, causing damages to the marine environment and threatening human life through contaminated seafood. To better understand the effect of HAB and marine algal toxins on marine environment and human health in China, this paper overviews HAB occurrence and marine algal toxin incidents, as well as their environmental and health effects in this country. HAB has been increasing rapidly along the Chinese coast since the 1970s, and at least 512 documented HAB events have occurred from 1952 to 2002 in the Chinese mainland. It has been found that PSP and DSP toxins are distributed widely along both the northern and southern Chinese coasts. The HAB and marine algal toxin events during the 1990s in China were summarized, showing that the HAB and algal toxins resulted in great damages to local fisheries, marine culture, quality of marine environment, and human health. Therefore, to protect the coastal environment and human health, attention to HAB and marine algal toxins is urgently needed from the environmental and epidemiological view.
Amnesia
;
chemically induced
;
Animals
;
China
;
epidemiology
;
Ciguatoxins
;
toxicity
;
Diarrhea
;
chemically induced
;
Dinoflagellida
;
Environment
;
Eukaryota
;
chemistry
;
Eutrophication
;
Fisheries
;
Food Contamination
;
Foodborne Diseases
;
epidemiology
;
etiology
;
Humans
;
Kainic Acid
;
analogs & derivatives
;
poisoning
;
Lethal Dose 50
;
Marine Toxins
;
chemistry
;
poisoning
;
toxicity
;
Neurotoxicity Syndromes
;
etiology
;
Okadaic Acid
;
poisoning
;
Oxocins
;
poisoning
;
Paralysis
;
chemically induced
;
Seawater
;
Shellfish Poisoning
5.Practical Effect of Sorafenib Monotherapy on Advanced Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis.
Soung Won JEONG ; Jae Young JANG ; Kwang Yeun SHIM ; Sae Hwan LEE ; Sang Gyune KIM ; Sang Woo CHA ; Young Seok KIM ; Young Deok CHO ; Hong Soo KIM ; Boo Sung KIM ; Kyoung Ha KIM ; Jung Hoon KIM
Gut and Liver 2013;7(6):696-703
BACKGROUND/AIMS: We investigated the effects of sorafenib monotherapy on advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT) in a clinical setting. METHODS: In total, 143 consecutive patients with unresectable HCC were treated with sorafenib. Among these patients, 30 patients with advanced HCC and PVTT (Vp3 or 4) were treated with sorafenib monotherapy. RESULTS: All patients had a performance status of 1 to 2 (Eastern Cooperative Oncology Group 1/2, 20/10) and Child-Pugh class A or B (A/B, 17/13). Eleven patients had modified Union for International Cancer Control stage IVA tumors, whereas 19 had stage IVB tumors. All patients had PVTT (Vp3, 6; Vp4, 24). Following sorafenib monotherapy, three patients (10.0%) had a partial response with PVTT revascularization, and nine (30.0%) had stable disease, with a disease control rate of 33.3%. The median overall survival was 3.1 months (95% confidence interval [CI], 2.70 to 3.50), and the median progression-free survival was 2.0 months (95% CI, 1.96 to 2.05). Fatigue and hand-foot skin reactions were the most troublesome side effects. CONCLUSIONS: A limited proportion of patients with advanced HCC and PVTT exhibited a remarkable outcome after sorafenib monotherapy, although the treatment results in this type of patient is extremely poor. Further studies to predict good responders to personalized therapy are warranted.
Adult
;
Aged
;
Aged, 80 and over
;
Anorexia/chemically induced
;
Antineoplastic Agents/adverse effects/*therapeutic use
;
Carcinoma, Hepatocellular/*drug therapy/pathology
;
Diarrhea/chemically induced
;
Disease-Free Survival
;
Fatigue/chemically induced
;
Female
;
Hand-Foot Syndrome/etiology
;
Humans
;
Kaplan-Meier Estimate
;
Liver Neoplasms/*drug therapy/pathology
;
Magnetic Resonance Imaging
;
Male
;
Middle Aged
;
Nausea/chemically induced
;
Neoplasm Invasiveness
;
Niacinamide/adverse effects/*analogs & derivatives/therapeutic use
;
Phenylurea Compounds/adverse effects/*therapeutic use
;
Portal Vein/*pathology
;
Proportional Hazards Models
;
Tomography, Spiral Computed
;
Venous Thrombosis/*drug therapy/pathology
6.Efficacy of concurrent chemoradiotherapy plus adjuvant chemotherapy on advanced cervical cancer.
Shun WANG ; Da-Shui ZHANG ; Tao PAN ; Sha LIU ; Ming-Kun WANG
Chinese Journal of Cancer 2010;29(11):959-963
BACKGROUND AND OBJECTIVEConcurrent chemoradiotherapy for cervical carcinoma develops rapidly and has become a common and standard therapy in recent years. Both the local control rate and survival rate of patients were increased and the risk of death fell by 30%-50%. This study aimed to explore the efficacy of concurrent chemoradiotherapy plus adjuvant chemotherapy on and the treatment compliance of the patients with advanced cervical squamous cell carcinoma.
METHODSA total of 156 patients with stage IIa-IIIb cervical squamous cell carcinoma were randomly divided into the concurrent chemoradiotherapy group (experimental group) and radiotherapy group (control group). Intracavity and external beam radiation therapy were administered. At point A, 40-48 Gy were given by 10-12 fractions; at point B, 46-50 Gy were given by 23-25 fractions. In the same time, experimental group was treated by cisplatin (DDP, 40 mg) on day 1, repeated every week. Ten days after radiation therapy, TP regimen was administered as adjuvant chemotherapy.
RESULTSFor the experimental and control groups, the objective response rates were 88.61% and 75.32%, 1-year survival rates were 88.57% and 70.77%, 1-year local control rates were 81.43% and 64.62%, 3-year survival rates were 82.14% and 57.69%, and 3-year local control rates were 75.00% and 46.15%, with significant differences (P<0.05). Quality of life of all patients were significantly improved after treatment (P<0.05).
CONCLUSIONConcurrent chemoradiotherapy plus adjuvant chemotherapy for advanced cervical cancer can improve short-term and long-term survival and local control rates of patients, improve the quality of life, and the toxicity can be tolerated.
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols ; adverse effects ; therapeutic use ; Carcinoma, Squamous Cell ; pathology ; therapy ; Chemoradiotherapy ; adverse effects ; Chemotherapy, Adjuvant ; Cisplatin ; adverse effects ; therapeutic use ; Diarrhea ; chemically induced ; etiology ; Dose Fractionation ; Female ; Humans ; Middle Aged ; Neoplasm Staging ; Paclitaxel ; Quality of Life ; Remission Induction ; Survival Rate ; Taxoids ; adverse effects ; therapeutic use ; Uterine Cervical Neoplasms ; pathology ; therapy ; Vomiting ; chemically induced ; etiology
7.Comparison of therapeutic effects of chemotherapy combined with radiotherapy versus chemotherapy alone in initial treatment of advanced gastric adenocarcinoma.
Yong ZHANG ; Yong-Hua YU ; Jin-Ming YU
Chinese Journal of Oncology 2009;31(7):557-558
Adenocarcinoma
;
drug therapy
;
pathology
;
radiotherapy
;
Adult
;
Aged
;
Antineoplastic Combined Chemotherapy Protocols
;
adverse effects
;
therapeutic use
;
Diarrhea
;
chemically induced
;
Disease Progression
;
Female
;
Follow-Up Studies
;
Humans
;
Leukopenia
;
chemically induced
;
etiology
;
Male
;
Middle Aged
;
Neoplasm Staging
;
Organoplatinum Compounds
;
administration & dosage
;
Radiotherapy, Conformal
;
adverse effects
;
Remission Induction
;
Stomach Neoplasms
;
drug therapy
;
pathology
;
radiotherapy
;
Taxoids
;
administration & dosage
8.Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer.
Hong-yan HUANG ; Ze-fei JIANG ; Tao WANG ; Shao-hua ZHANG ; Li BIAN ; Yang CAO ; Shi-kai WU ; San-tai SONG
Chinese Journal of Oncology 2011;33(11):850-853
OBJECTIVETo evaluate retrospectively the efficacy and toxicity of capecitabine-based chemotherapy in the treatment of advanced breast cancer.
METHODSThree hundred and seventy-six patients with advanced breast cancer were treated with capecitabine-based chemotherapy regimens in our department from Sep 2002 to Sep 2009. They were divided into 3 groups. The group 1 was treated with capecitabine 1000 mg/m(2) orally twice daily on d1-d14, repeated every 3 weeks. The group 2 was treated with capecitabine as group 1, and combined with docetaxel 60 - 75 mg/m(2) intravenous infusion on d1, repeated every 3 weeks. The group 3 was treated with capecitabine as group 1, and combined with vinorelbine 25 mg/m(2) intravenous infusion on d1 and d8, repeated every 3 weeks. The median treatment period of treatment was 3 cycles.
RESULTSAmong the 376 patients, 218 patients were evaluable for response. In the group 1 the objective response rate (ORR) was 12.8% and the clinical benefit rate (CBR) was 21.6%. The CBR but not ORR of first line therapy with capecitabine was 35.2%, significantly higher than that of more than first line therapy (17.1%, P < 0.01). The ORRs for group 2 and group 3 were 53.8% and 36.4%, respectively. In the group 2 there was no significant difference in the ORR between the first line therapy and more than first line therapy. In the group 3 the ORR of first line therapy of NX regimen was 36.4%, significantly higher than that of more than first line therapy (16.7%, P < 0.01).
CONCLUSIONSThe capecitabine-based chemotherapy is effective and tolerable, and can be used not only in first line but also more than first line therapy. The single agent maintenance chemotherapy after response to combined chemotherapy can prolonge the duration of treatment for patients with metastatic breast cancer.
Adult ; Agranulocytosis ; chemically induced ; Antimetabolites, Antineoplastic ; administration & dosage ; adverse effects ; therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; adverse effects ; therapeutic use ; Breast Neoplasms ; drug therapy ; pathology ; Capecitabine ; Deoxycytidine ; administration & dosage ; adverse effects ; analogs & derivatives ; therapeutic use ; Diarrhea ; chemically induced ; Disease Progression ; Disease-Free Survival ; Female ; Fluorouracil ; administration & dosage ; adverse effects ; analogs & derivatives ; therapeutic use ; Follow-Up Studies ; Hand-Foot Syndrome ; etiology ; Humans ; Leukopenia ; chemically induced ; Maintenance Chemotherapy ; Middle Aged ; Neoplasm Staging ; Remission Induction ; Retrospective Studies ; Taxoids ; administration & dosage ; Vinblastine ; administration & dosage ; analogs & derivatives
9.Effecacy of three-dimensional conformal radiation therapy combined with Tegafur for postoperative recurrent rectal carcinoma.
Chinese Journal of Oncology 2011;33(4):299-301
OBJECTIVETo observe the local control rate, survival time and side effect of three-dimensional conformal radiation therapy combined with Tegafur for postoperative recurrent rectal carcinoma.
METHODSForty patients with postoperative recurrent rectal carcinoma received three-dimensional conformal radiation therapy, 1.8 - 2.0 Gy/once, 5 times every week and the total dose was 54 - 65 Gy. At the same time, the patients took Tegafur orally 40 mg/m(2) twice per day for consecutive 28 days, and one cycle lasted for 42 days. The chemotherapy was applied for 2 cycles after radiotherapy.
RESULTSThe total effective rate (CR + PR) was 70.0%, improvement rate was 90.0%, 1-year survival rate was 70.0%, and 1-year local control rate was 62.5%. There was only a little side effect.
CONCLUSIONSThree-dimensional conformal radiation therapy combined with Tegafur for postoperative recurrent rectal carcinoma have definite effect, with a high local control rate, and patients well tolerance the treatment without serious side effect. It can apparently improve the life quality of the patients.
Adenocarcinoma ; drug therapy ; radiotherapy ; surgery ; Adult ; Aged ; Antimetabolites, Antineoplastic ; adverse effects ; therapeutic use ; Combined Modality Therapy ; Diarrhea ; etiology ; Exanthema ; chemically induced ; etiology ; Female ; Humans ; Leukopenia ; etiology ; Male ; Middle Aged ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Postoperative Period ; Quality of Life ; Radiotherapy, Conformal ; adverse effects ; Rectal Neoplasms ; drug therapy ; radiotherapy ; surgery ; Remission Induction ; Survival Rate ; Tegafur ; adverse effects ; therapeutic use
10.Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.
Bing-He XU ; Ze-Fei JIANG ; Daniel CHUA ; Zhi-Min SHAO ; Rong-Cheng LUO ; Xiao-Jia WANG ; Dong-Geng LIU ; Winnie YEO ; Shi-Ying YU ; Beth NEWSTAT ; Alka PRESTON ; Anne-Marie MARTIN ; Hai-Dong CHI ; Li WANG
Chinese Journal of Cancer 2011;30(5):327-335
Overexpression of human epidermal growth factor receptor-2 (HER2) in metastatic breast cancer (MBC) is associated with poor prognosis. This single-arm open-label trial (EGF109491; NCT00508274) was designed to confirm the efficacy and safety of lapatinib in combination with capecitabine in 52 heavily pretreated Chinese patients with HER2-positive MBC. The primary endpoint was clinical benefit rate (CBR). Secondary endpoints included progression-free survival (PFS), time to response (TTR), duration of response (DoR), central nervous system (CNS) as first site of relapse, and safety. The results showed that there were 23 patients with partial responses and 7 patients with stable disease, resulting in a CBR of 57.7%. The median PFS was 6.34 months (95% confidence interval, 4.93-9.82 months). The median TTR and DoR were 4.07 months (range, 0.03-14.78 months) and 6.93 months (range, 1.45-9.72 months), respectively. Thirteen (25.0%) patients had new lesions as disease progression. Among them, 2 (3.8%) patients had CNS disease reported as the first relapse. The most common toxicities were palmar-plantar erythrodysesthesia (59.6%), diarrhea (48.1%), rash (48.1%), hyperbilirubinemia (34.6%), and fatigue (30.8%). Exploratory analyses of oncogenic mutations of PIK3CA suggested that of 38 patients providing a tumor sample, baseline PIK3CA mutation status was not associated with CBR (P = 0.639) or PFS (P = 0.989). These data confirm that the lapatinib plus capecitabine combination is an effective and well-tolerated treatment option for Chinese women with heavily pretreated MBC, irrespective of PIK3CA status.
Adult
;
Aged
;
Antineoplastic Combined Chemotherapy Protocols
;
adverse effects
;
therapeutic use
;
Asian Continental Ancestry Group
;
Breast Neoplasms
;
drug therapy
;
genetics
;
metabolism
;
pathology
;
Capecitabine
;
Class I Phosphatidylinositol 3-Kinases
;
Deoxycytidine
;
administration & dosage
;
adverse effects
;
analogs & derivatives
;
Diarrhea
;
chemically induced
;
Disease Progression
;
Disease-Free Survival
;
Exanthema
;
chemically induced
;
Female
;
Fluorouracil
;
administration & dosage
;
adverse effects
;
analogs & derivatives
;
Hand-Foot Syndrome
;
etiology
;
Humans
;
Middle Aged
;
Mutation
;
Neoplasm Staging
;
Phosphatidylinositol 3-Kinases
;
genetics
;
Quinazolines
;
administration & dosage
;
adverse effects
;
Receptor, ErbB-2
;
metabolism
;
Remission Induction